Oncology Intelligence
Focused analysis of global oncology pipelines, immunotherapy breakthroughs, regulatory acceleration pathways and competitive strategy across major pharmaceutical markets.
Oncology remains the largest therapeutic category globally.
Immuno-oncology, ADCs, targeted therapies and combination regimens are redefining competitive positioning.
From Intravenous Infusion to Oral Administration: Paclitaxel Oral Solution Gains a New Indication for Breast Cancer
October 15, 2026
China’s NMPA approved paclitaxel oral solution on October 8, 2026 for recurrent or metastatic HER2-negative breast cancer, supported by the OPTIMAL Phase III non-inferiority trial.
KRAS Mutations and Precision Oncology: From KRAS G12C Inhibitors to Next-Generation RAS-Targeted Therapies
October 13, 2026
How KRAS mutation subtypes shape targeted treatment, from approved KRAS G12C inhibitors in China to investigational RAS(ON) inhibitors such as daraxonrasib.
Complete Guide to Lung Cancer Treatment in China: Costs, Leading Hospitals, and What International Patients Should Know
September 29, 2026
A reference guide to lung cancer treatment costs, hospitals, and treatment options in China for international patients, from VATS surgery and SBRT to targeted therapy and immunotherapy.
What Is the Difference Between Acute and Chronic Leukemia? DengYue RX Explains Leukemia Types and Pharmaceutical Supply
September 24, 2026
AML, ALL, CML, and CLL differ in disease progression and treatment needs, which is why DengYue RX sources leukemia medicines by specific product rather than the general term “leukemia medicine.”
Rituximab Procurement Options: Different Budget Solutions from Originator Drugs to Biosimilars
September 23, 2026
As Rituximab biosimilars expand the supply landscape alongside originator products, hospitals, pharmacies, and distributors can weigh brand requirements against budget when planning procurement.
2026 CSCO Guideline Includes Nolgileucel: A Key Development for China-Originated TIL Therapy
September 20, 2026
Nolgileucel (GC101), a China-originated TIL therapy, has entered the 2026 CSCO melanoma guideline recommendations, backed by the MIZAR-003 Phase II study in anti-PD-1-resistant advanced melanoma.
Oral Medications for Prostate Cancer: How Can Patients Achieve More Structured Home-Based Management?
September 20, 2026
Oral androgen receptor pathway inhibitors, abiraterone, and oral GnRH antagonists let eligible prostate cancer patients manage part of their treatment at home, supported by regular PSA, testosterone, and safety monitoring.
Global PD-1 Competition Heats Up: China Emerges as a Major Force in Cancer Immunotherapy
September 18, 2026
From toripalimab and tislelizumab’s FDA approvals to ivonescimab’s PD-1/VEGF bispecific breakthrough, China’s PD-1 sector is moving from domestic scale to global clinical and regulatory leadership.
What Do RET and BRAF Gene Changes Mean in Thyroid Cancer?
September 11, 2026
An overview of RET, BRAF, NTRK and RAS genetic alterations in thyroid cancer, the role of molecular testing, and how precision medicine is influencing treatment decisions.
New Drug for Biliary Tract Cancer! A Japanese Innovation Enters China, Adding a New Variable to the Global FGFR Landscape
September 10, 2026
China has approved tasurgratinib succinate tablets for unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements, adding another FGFR-targeted option to China’s precision oncology landscape.
Ensartinib Approved for Adjuvant Treatment of ALK-Positive NSCLC, Marking Another Step Forward for China’s ALK Inhibitors
September 04, 2026
Ensartinib Approved for Adjuvant Treatment of ALK-Positive NSCLC, Marking Another Step Forward for China’s ALK Inhibitors
What Is Synthetic Lethality? How PARP Inhibitors Work in Cancer Treatment
September 03, 2026
Learn how synthetic lethality works in cancer treatment and how PARP inhibitors target tumors with BRCA1/2 alterations or homologous recombination deficiency.
Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology
August 28, 2026
The U.S. FDA approved zanidatamab with tislelizumab and chemotherapy as a first-line treatment option for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
Bone Marrow Protection Throughout Chemotherapy: Trilaciclib Approved for a New Indication, Extending from First-Line to Post-Relapse Treatment
August 27, 2026
China has approved a new indication for trilaciclib in relapsed extensive-stage small cell lung cancer, extending pre-chemotherapy bone marrow protection to Topotecan-containing regimens.
Breaking Through for an Asian Cancer: China’s Innovation Rewrites the Future of Nasopharyngeal Cancer Treatment
August 25, 2026
Izalontamab brengitecan, the world’s first approved bispecific ADC, is opening new treatment possibilities for patients with recurrent or metastatic nasopharyngeal cancer and expanding into other solid tumors.
The 30-Year Chemotherapy Standard Faces a New Challenge: China’s PD-1 Serplulimab Breaks New Ground in Gastric Cancer Treatment
August 25, 2026
ASTRUM-006 explores a chemotherapy-sparing perioperative strategy using China’s PD-1 inhibitor serplulimab in PD-L1-positive resectable gastric cancer.
Sevabertinib for HER2-Mutant NSCLC in China: A New Targeted Treatment Option
August 20, 2026
Sevabertinib offers a new targeted treatment option in China for adults with advanced or metastatic non-squamous NSCLC harboring activating HER2 mutations after prior systemic therapy.
Current Status of Immunotherapy for Bladder Cancer: From BCG to Precision Combination Therapy
August 19, 2026
Explore the current landscape of bladder cancer immunotherapy, from BCG for high-risk NMIBC to PD-1/PD-L1 inhibitors and emerging combination strategies.
Are Women More Prone to Thyroid Cancer? Causes and Prevention Explained
August 17, 2026
Women are diagnosed with thyroid cancer more often than men. Learn why women may have a higher incidence, common symptoms, risk factors, prevention strategies, and current treatment options.
Where Pancreatic Cancer Develops Matters: Understanding Pancreatic Head Cancer vs. Body and Tail Cancer
August 13, 2026
Learn how pancreatic head cancer differs from pancreatic body and tail cancer, including symptoms, diagnosis, surgery, chemotherapy, and the role of molecular testing.